Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Merck’s RSV treatment for infants is approved by FDA
Health and Wellness

Merck’s RSV treatment for infants is approved by FDA

Last updated: June 9, 2025 4:20 pm
Share
Merck’s RSV treatment for infants is approved by FDA
SHARE

A groundbreaking development in the fight against respiratory syncytial virus (RSV) was announced on Monday with the approval of Merck’s clesrovimab, now known as Enflonsia, by the Food and Drug Administration. This monoclonal antibody product is designed to protect infants under the age of 12 months from the severe effects of RSV, offering a new tool in combating this common and dangerous respiratory infection.

Priced at $556 per dose, Enflonsia enters the market at the same price point as its competitor, Beyfortus (nirsevimab) from Sanofi and AstraZeneca. However, Enflonsia offers a unique advantage with a single dosage for all infants, regardless of weight, simplifying the administration process for healthcare providers and families. This streamlined approach may help alleviate some logistical challenges faced during the rollout of other RSV prevention products.

While Enflonsia is currently approved for use only in a child’s first year, Merck is actively conducting studies to potentially expand its authorization to include high-risk infants in their second RSV season. The efficacy of Enflonsia is promising, with a significant reduction in medically attended lower respiratory infections and RSV hospitalizations, providing much-needed relief to families and the healthcare system.

The approval of Enflonsia comes at a time of rapid advancements in RSV prevention, with Pfizer’s Abrysvo vaccine for pregnant individuals also making strides in protecting newborns from RSV. With multiple options now available, healthcare providers have more tools at their disposal to safeguard vulnerable populations against this respiratory virus.

As the availability of Enflonsia begins in July, the upcoming RSV season stands to benefit from this innovative preventive measure. The potential impact of Enflonsia in reducing the burden of RSV-related illnesses underscores the importance of continued research and development in the field of pediatric infectious diseases.

See also  Early-onset cancer rates rise for multiple types among Americans under 50

In light of recent changes within the Advisory Committee on Immunization Practices, the landscape of vaccine recommendations may shift, but the commitment to advancing public health through effective interventions remains steadfast. The approval of Enflonsia marks a significant milestone in the ongoing battle against RSV, offering hope for a future where the impact of this respiratory virus is greatly diminished.

TAGGED:ApprovedFDAinfantsMercksRSVTreatment
Share This Article
Twitter Email Copy Link Print
Previous Article Leaked Priscilla Presley Video Throws Grenade into ‘Elder-Abuse’ Battle Leaked Priscilla Presley Video Throws Grenade into ‘Elder-Abuse’ Battle
Next Article TWP Resort 2026 Collection | Vogue TWP Resort 2026 Collection | Vogue
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Xbox consoles, controllers, and games are getting more expensive

Microsoft made headlines on Thursday with the announcement of price increases for its Xbox consoles,…

May 1, 2025

Deal of the Day: Get a $5 Subscription to WIRED

Technology is constantly evolving, and it's essential for educators to stay informed about the latest…

January 28, 2025

Janelle Rohner Refunds Fans Amid GLP-1 Medication Backlash

Janelle Rohner, a well-known wellness influencer, recently faced backlash after admitting to using a GLP-1…

April 28, 2025

Dividend Growth and Stability: PepsiCo’s (PEP) Strength in the Consumer Staples Sector

PepsiCo, Inc. (NASDAQ:PEP) is featured in the 12 Best Dividend Aristocrat Stocks to Invest in…

October 3, 2025

J6 Sedition Cases Actually Attack On Free Speech – Trump Can Be Like Thomas Jefferson |

In my role as a journalist advocating for those affected by the January 6 events…

April 16, 2025

You Might Also Like

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown
Health and Wellness

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown

October 10, 2025
No, circumcision doesn’t cause autism
Health and Wellness

No, circumcision doesn’t cause autism

October 10, 2025
Jay Shetty and his health advice are everywhere. It’s by design
Health and Wellness

Jay Shetty and his health advice are everywhere. It’s by design

October 10, 2025
STAT+: Key GOP lawmaker tones down rhetoric on medical care for immigrants
Health and Wellness

STAT+: Key GOP lawmaker tones down rhetoric on medical care for immigrants

October 9, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?